If your returns to shareholders are preventing treatment becoming available to people, then it is wrong and you should have a policy in a company that allows full access.Trounson, who now heads the California Institute of Regenerative Medicine - the world's biggest stem cell research centre - is concerned that the technologies he helped create for all humanity are mostly denied to people in the